1
40
2
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
Citation List Month
Backlog
URL Address
<a href="http://doi.org/10.1002/(SICI)1097-0142(19970401)79:7%3C1428::AID-CNCR21%3E3.0.CO" target="_blank" rel="noreferrer">http://doi.org/10.1002/(SICI)1097-0142(19970401)79:7%3C1428::AID-CNCR21%3E3.0.CO</a>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain
Publisher
An entity responsible for making the resource available
Cancer
Date
A point or period of time associated with an event in the lifecycle of the resource
1997
Subject
The topic of the resource
Female; Humans; Analgesics; Middle Aged; Double-Blind Method; Cross-Over Studies; Comparative Study; Neoplasms/complications; Delayed-Action Preparations; Drug Evaluation; Hydromorphone/administration & Male; Opioid/administration & dosage; Oxycodone/administration & Pain/drug therapy
Creator
An entity primarily responsible for making the resource
Hagen NA; Babul N
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1002/(SICI)1097-0142(19970401)79:7%3C1428::AID-CNCR21%3E3.0.CO" target="_blank" rel="noreferrer">10.1002/(SICI)1097-0142(19970401)79:7%3C1428::AID-CNCR21%3E3.0.CO</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. PedPalASCNET does not hold any rights over the resource listed here. All rights are retained by the journal listed under publisher and/or the creator(s).
Type
The nature or genre of the resource
Journal Article
Description
An account of the resource
BACKGROUND: The use of oxycodone to treat chronic cancer pain has been hampered by its short elimination half-life, which necessitates administration every 4 hours. This study compared the clinical efficacy and safety of a novel oxycodone formulation with that of hydromorphone in the treatment of cancer pain. METHODS: In a double-blind crossover study, 44 patients with stable cancer pain were randomized to controlled-release oxycodone or controlled-release hydromorphone, each given every 12 hours for 7 days. Pain intensity, nausea, and sedation were assessed by patients four times daily, and breakthrough analgesia was recorded. RESULTS: Thirty-one patients completed the study (18 women, 13 men; mean age, 56 +/- 3 years) and received a final controlled-release oxycodone dose of 124 +/- 22 mg per day and a final controlled-release hydromorphone dose of 30 +/- 6 mg per day. There were no significant differences between treatments in overall Visual Analogue Scale (VAS) pain intensity (VAS 28 +/- 4 mm vs. 31 +/- 4 mm), categorical pain intensity (1.4 +/- 0.1 vs. 1.5 +/- 0.1), daily rescue analgesic consumption (1.4 +/- 0.3 vs. 1.6 +/- 0.3), sedation scores (24 +/- 4 mm vs. 18 +/- 3 mm), nausea scores (15 +/- 3 mm vs. 13 +/- 3 mm), or patient preference. Two patients experienced hallucinations on controlled-release hydromorphone, but none did while receiving controlled-release oxycodone. CONCLUSIONS: Controlled-release oxycodone demonstrated excellent pharmacodynamic characteristics, analgesic efficacy, and safety as compared with controlled-release hydromorphone and represents an important new therapeutic option for cancer pain management.
1997
Analgesics
Babul N
Backlog
Cancer
Comparative Study
Cross-Over Studies
Delayed-Action Preparations
Double-Blind Method
Drug Evaluation
Female
Hagen NA
Humans
Hydromorphone/administration & Male
Journal Article
Middle Aged
Neoplasms/complications
Opioid/administration & dosage
Oxycodone/administration & Pain/drug therapy
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
Citation List Month
Backlog
URL Address
<a href="http://doi.org/10.1002/1097-0142(19940915)74:6%3C1808::aid-cncr2820740625%3E3.0.co" target="_blank" rel="noreferrer">http://doi.org/10.1002/1097-0142(19940915)74:6%3C1808::aid-cncr2820740625%3E3.0.co</a>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Comparative clinical efficacy and safety of immediate release and controlled release hydromorphone for chronic severe cancer pain
Publisher
An entity responsible for making the resource available
Cancer
Date
A point or period of time associated with an event in the lifecycle of the resource
1994
Subject
The topic of the resource
Female; Humans; Male; Pain Measurement; Middle Aged; Double-Blind Method; Drug Administration Schedule; Chronic disease; Pain/drug therapy/etiology; Neoplasms/complications; Delayed-Action Preparations; Hydromorphone/administration & dosage
Creator
An entity primarily responsible for making the resource
Hays H; Hagen N; Thirlwell M; Dhaliwal H; Babul N; Harsanyi Z; Darke AC
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1002/1097-0142(19940915)74:6%3C1808::aid-cncr2820740625%3E3.0.co" target="_blank" rel="noreferrer">10.1002/1097-0142(19940915)74:6%3C1808::aid-cncr2820740625%3E3.0.co</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. PedPalASCNET does not hold any rights over the resource listed here. All rights are retained by the journal listed under publisher and/or the creator(s).
Type
The nature or genre of the resource
Journal Article
Description
An account of the resource
BACKGROUND. The short elimination half-life of hydromorphone necessitates 4-hourly dosing to maintain optimal levels of analgesia in patients with chronic cancer pain. The purpose of this study was to compare the clinical efficacy and safety of controlled release hydromorphone administered every 12 hours and immediate release hydromorphone administered every 4 hours in patients with chronic severe cancer pain. METHODS: Forty-eight patients with stable chronic severe cancer pain were randomized, in a double-masked crossover study, to controlled release hydromorphone every 12 hours or immediate release hydromorphone every 4 hours for 7 days each. Pain intensity was assessed using a visual analog scale (VAS) and the Present Pain Intensity Index of the McGill Pain Questionnaire. Nausea and sedation were also assessed using a VAS. Assessments were made by the patient four times a day at 7:00 a.m., 11:00 a.m., 3:00 p.m., and 7:00 p.m. Use of rescue hydromorphone also was recorded by the patient. RESULTS: Forty-five patients completed the study (26 women, 19 men; mean age, 57.1 +/- 13.6 years) and received a mean daily dose of 76 +/- 133 mg (range, 6-768 mg). There were no significant differences between controlled release hydromorphone and immediate release hydromorphone in overall VAS pain intensity scores (19 +/- 14 vs. 20 +/- 14 mm), ordinal pain intensity scores (1.2 +/- 0.8 vs. 1.2 +/- 0.8) and pain scores by day of treatment or time of day. The daily rescue analgesic consumption during controlled release hydromorphone and immediate release hydromorphone did not differ significantly overall (1.1 +/- 1.1 vs. 1.0 +/- 1.1 doses per day) or with respect to time of day. There were no significant differences in overall VAS sedation scores (18 +/- 18 mm vs. 19 +/- 18 mm) and in overall mean VAS nausea scores (12 +/- 15 mm vs. 11 +/- 14 mm) between controlled release hydromorphone and immediate release hydromorphone. CONCLUSIONS. Controlled release hydromorphone administered every 12 hours is as effective as immediate release hydromorphone administered every 4 hours in the management of patients with chronic severe cancer pain. The benefits of controlled release hydromorphone lie in the convenience of its capsule formulation, which can be sprinkled on soft food, and its 12-hour duration of action, which allows patients uninterrupted sleep and improved compliance.
1994
Babul N
Backlog
Cancer
Chronic Disease
Darke AC
Delayed-Action Preparations
Dhaliwal H
Double-Blind Method
Drug Administration Schedule
Female
Hagen N
Harsanyi Z
Hays H
Humans
Hydromorphone/administration & dosage
Journal Article
Male
Middle Aged
Neoplasms/complications
Pain Measurement
Pain/drug therapy/etiology
Thirlwell M